Differentiating treatment damage and new tumor growth with MRI after treatment for brain tumor

31P metabolic MRI in the differentiation between TRA and TP in post-treatment glioma patients - 31P metabolic MRI in the differentiation between TRA and TP in post-treatment glioma patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58501

Enrollment

Registered

2025-10-15

Start date

2026-03-22

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma, Glial tumor, primary brain tumor Brain tumor

Interventions

31P magnetic resonance spectroscopic imaging

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age > 18 years;Diagnosed with high-grade glioma (according to WHO 2021 classification system) and treated with surgery, chemo- and radiotherapy;Follow up MRI =3 months after the end of the treatment with standard-of-care temozolomide-based concomitant chemoradiation.;First moment (since treatment) of uncertainty regarding the diagnosis: pseudoprogression or tumor recurrence. The determination of ‘uncertainty’ is made by the diagnosing/treating physician, preferably in the multidisciplinary tumor board, based on available clinical and standard-of-care MRI-data, which generally includes perfusion-MRI (for monitors, the report (or addendum to the report) will state: “suitable candidate for 31P MRS Study”);Previous usage of bevacizumab as a symptom treatment is allowed.Capable of giving informed consent, as determined by treating physician.

Exclusion criteria

Exclusion criteria: An enhancing lesion size of <1 cm on MRI;A lesion with significant blooming artefacts, as observed on previous MR images, for example due to (post-treatment) hemorrhages;Any other concomitant disease that may influence MRI, this includes but is not limited to: cerebral inflammatory diseases and other cancers with brain- or leptomeningeal metastases;Start of additional treatment between the regular follow-up MRI exam and our additional 31P-MRS sequence.Patients that suffer from (acute) worsening of clinical symptoms caused by the high-grade glioma that renders them unable to give informed consent or unable to undergo the 31P-MRS sequence.

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of the ratio of phospho-mono-esters and phospho-di-esters at the region of interest in the differentiation between tumor progression and treatment-related abnormalitities.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Contacts

Public ContactS.D.A. Herings

Radboud Universitair Medisch Centrum

siem.herings@radboudumc.nl024-3614422

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 25, 2026